Search Results
Your search for ,iII matches 9386 pages
Showing 701 - 750
Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-duration acalabrutinib/venetoclax—with or without obinutuzumab—with investigator’s choice of...
Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer
A novel immunotherapy may offer a new option for patients with bladder cancer who no longer respond to bacillus Calmette-Guérin (BCG), according to a study presented on December 5 at the 2024 Society of Urologic Oncology Annual Meeting in Dallas. The therapy, cretostimogene grenadenorepvec, is an...
Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer
A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
De-escalated Neoadjuvant Treatment Adding Nab-Paclitaxel or Docetaxel/Carboplatin to Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer
In a Chinese phase III trial (HELEN-006) reported in The Lancet Oncology, Chen et al found that the de-escalated neoadjuvant treatment with the addition of nab-paclitaxel to trastuzumab/pertuzumab produced a higher pathologic complete response rate (pCR) vs docetaxel/carboplatin plus...
Understanding the Assessment and Treatment of High-Risk Myelofibrosis
At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...
Temozolomide Plus Radiotherapy for Low-Grade Gliomas
Based on the phase III E3F05 trial, conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), the combination of radiation therapy and temozolomide appeared to be more effective than radiotherapy alone in the treatment of low-grade gliomas. The trial followed 172 patients for more than 10...
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma
Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...
Adding Chemoradiation in Perioperative Gastric Cancer Treatment Improves Pathologic Response Rates Without Survival Benefit
Adding chemoradiation to perioperative chemotherapy improves pathologic complete response rates in patients with resectable gastric cancer but does not extend overall survival, according to data presented at the European Society for Medical Oncology (ESMO) Congress 20241 and published...
In Treatment of Transplant-Ineligible Myeloma, Addition of Isatuximab Improves Outcomes
In the phase III IMROZ trial, the addition of the anti-CD38 monoclonal antibody isatuximab-irfc to bortezomib, lenalidomide, and dexamethasone (VRd) was more effective than VRd alone as initial therapy in patients ≤ 80 years with newly diagnosed multiple myeloma ineligible for transplant,...
Toripalimab Plus Chemotherapy in First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
In a Chinese phase III trial (EXTENTORCH) reported in JAMA Oncology, Cheng et al reported that the addition of the immunoglobulin G4 PD-1–blocking antibody toripalimab to first-line chemotherapy with etoposide plus cisplatin or carboplatin (EP) improved progression-free survival among patients with ...
Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer
As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study showed no significant differences in progression-free or overall survival with first-line lenvatinib/pembrolizumab vs chemotherapy in patients with...
Daratumumab Induction Regimen in Transplant-Ineligible Patients Newly Diagnosed with Multiple Myeloma
In the phase III CEPHEUS trial,1 the achievement of undetectable measurable residual disease (or MRD negativity)—the primary endpoint—was met by 61% of patients with transplant-ineligible or deferred newly diagnosed multiple myeloma treated with the monoclonal antibody daratumumab plus bortezomib, ...
Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer
In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-free survival vs continuation of first-line oxaliplatin-based chemotherapy in patients with advanced...
Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin
As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III...
Overall Survival Not Improved With Maintenance Niraparib in Advanced Ovarian Cancer
The final overall survival analysis of the phase III PRIMA trial found no survival benefit for maintenance niraparib over placebo in advanced ovarian cancer. However, the PARP inhibitor continued to exert a sustained progression-free survival benefit, investigators reported at the European Society...
Glofitamab or Rituximab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory DLBCL
As reported in The Lancet by Abramson et al, the phase III STARGLO trial has shown significantly improved overall survival with glofitamab plus gemcitabine/oxaliplatin vs rituximab plus gemcitabine/oxaliplatin in patients with transplant-ineligible relapsed or refractory diffuse large B-cell...
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas
Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...
Nodal Burden and Recurrence in Patients With Breast Cancer With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy
In a retrospective study (OPBC-05/ICARO) reported in the Journal of Clinical Oncology, Giacomo Montagna, MD, MPH, of Memorial Sloan Kettering Cancer Center, New York, and colleagues found that nodal burden in patients with breast cancer with residual isolated tumor cells after neoadjuvant...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
PEACE-3: Enzalutamide Plus Radium-223 Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Initial analysis from the PEACE-3 trial suggests that the addition of radium-223 dichloride to enzalutamide could offer a promising new first-line treatment option for patients with metastatic castration-resistant prostate cancer, according to data presented by lead study author, Silke Gillessen,...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
HIMALAYA: 5-Year Analysis Confirms Survival Benefit of STRIDE Regimen in Hepatocellular Carcinoma
An updated overall survival analysis of the phase III HIMALAYA study, now at 5 years, confirms the benefit for the STRIDE regimen of the monoclonal antibodies durvalumab plus tremelimumab in unresectable hepatocellular carcinoma.1 [The STRIDE regimen consists of a single priming dose of...
LEAP-012: Combination of Therapies Extends Progression-Free Survival in Intermediate-Stage Hepatocellular Carcinoma
The combination of the VEGF tyrosine kinase inhibitor lenvatinib, the PD-1 inhibitor pembrolizumab, and transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with intermediate-stage hepatocellular carcinoma (HCC) compared with TACE alone, according to...
Overall Survival Analysis Confirms Pembrolizumab Regimen as Standard of Care for Triple-Negative Breast Cancer
For women with early-stage triple-negative breast cancer, KEYNOTE-522 changed the treatment paradigm several years ago. Support for neoadjuvant use of the PD-1 inhibitor pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, was bolstered by the positive overall survival analysis...
HypoG-01 Trial: Reducing the Treatment Time for Breast Cancer Nodal Irradiation
A 3-week moderately hypofractionated radiotherapy regimen has been found to be noninferior to the 5-week fractionation when irradiating nodal areas in patients with breast cancer, according to data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1 The 5-year results of...
I-SPY2.2: Dato-DXd Plus Durvalumab Yields High Pathologic Response Rate in Breast Cancer Subset
In the neoadjuvant I-SPY2.2 trial, a treatment strategy including the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), partnered with the PD-L1 inhibitor durvalumab, yielded a high pathologic complete response rate, especially in immune-positive and ‘all-negative’ subtypes.1...
Highlights From the ESMO Congress 2024
The European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona featured several groundbreaking trials with the potential to significantly influence clinical practice. These studies highlighted the benefits of new combination immunotherapy strategies and innovative approaches in the...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III -CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
Penpulimab Combination Therapy for First-Line Treatment of Hepatocellular Carcinoma
The National Medical Products Administration (NMPA) of China has accepted a supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination with the multikinase inhibitor anlotinib for the first-line treatment of advanced hepatocellular carcinoma...
Global Adaptive Platform Trial for Glioblastoma to Evaluate Novel ATM Kinase Inhibitor
The Global Coalition for Adaptive Research (GCAR) announced an agreement to evaluate AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor developed by AstraZeneca, in GCAR’s Glioblastoma Adaptive Global Innovative Learning Environment trial (GBM AGILE; ClinicalTrials.gov identifier...
Perioperative Toripalimab in Locoregionally Advanced Nasopharyngeal Carcinoma
Hai-Qiang Mai, MD, of the Department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center in Guangzhou, China, and colleagues reported their findings from a single-center phase II trial in The Lancet Oncology.1 They found that the addition of perioperative toripalimab to concurrent...
Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer
Based on results from the ongoing multicenter phase III CHIPOR trial, which were reported in The Lancet Oncology Jean-Marc Classe, MD, PhD, Head of the Oncological Surgery Department at the Institut de Cancérologie de l’Ouest, Saint Herblain, France, and colleagues, the addition of hyperthermic...
Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset
The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial.1 MEGAMOST was designed to evaluate...
Determining the Optimal First-Line Management of Advanced Classical Hodgkin Lymphoma
“While clinical trials emphasize improvement in cure rates for patients with advanced classical Hodgkin lymphoma, an important goal is reducing the potential long-term effects of treatment,” commented Iris Isufi, MD, of the Smilow Cancer Hospital and Yale Cancer Center, New Haven, Connecticut, and ...
4-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
Neoadjuvant chemotherapy with vs without the PD-1 inhibitor nivolumab conferred a higher pathologic complete response rate and long-term event-free survival benefit in Asian patients with resectable non–small cell lung cancer (NSCLC), according to the global phase III CheckMate 816 trial. At the...
Performance of First-Line Chemotherapy Regimens in Unresectable Advanced or Metastatic Pancreatic Cancer
In a meta-analysis reported in The Lancet Oncology, Mastrantoni et al identified first-line chemotherapy regimens associated with better outcomes in patients with unresectable advanced or metastatic pancreatic cancer. Study Details The Bayesian network analysis included 79 randomized controlled...
Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity
In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity. Study Details In the...
Immunotherapy Combination for Cutaneous Melanoma
Presurgical treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab may improve outcomes in patients with stage III cutaneous melanoma, according to a recent study published by Davar et al in Cancer Cell. The findings supported the development of vidutolimod for...
Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma
In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation. Study Details In the double-blind Alliance for Clinical Trials...
Treatment Advances, Predictive Biomarkers May Improve Urothelial Carcinoma Care
Recent advances in urothelial carcinoma treatments may offer a path to curative care for more patients, including those with high-risk localized, muscle-invasive disease, according to an editorial published by Milowsky in The New England Journal of Medicine. The findings indicated that...
In Case You Missed It: Roundup From ESMO Congress 2024
In addition to our in-depth analysis of important clinical trials presented at the European Society for Medical Oncology (ESMO) Congress 2024, there is always room for more coverage from The ASCO Post, including these brief summaries of other presentations of interest. They focus on a potential...
Addition of Adjuvant Epirubicin to Docetaxel/Cyclophosphamide in Early TOP2A-Normal Breast Cancer
As reported in the Journal of Clinical Oncology by Jensen et al, the final analysis of the phase III Danish DBCG07-READ trial showed improved 10-year outcomes with the addition of epirubicin to docetaxel/cyclophosphamide adjuvant therapy in patients with TOP2A-normal breast cancer. The primary...
Addition of Inavolisib to Palbociclib/Fulvestrant in PIK3CA-Mutated Advanced Breast Cancer
In a phase III trial (INAVO120) reported in The New England Journal of Medicine, Nicholas C. Turner, MD, PhD, of Royal Marsden Hospital and the Institute of Cancer Research, London, and colleagues found that the addition of inavolisib to palbociclib/fulvestrant improved progression-free survival...
Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (SCLC) in an interim analysis of the phase II IDeate-Lung01 study.1 The findings were presented at the International Association for...
TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC
The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously treated patients with advanced non–small cell lung cancer (NSCLC), according to the phase III,...
CARMEN-LC03: Tusamitamab Ravtansine vs Docetaxel in Previously Treated Advanced Nonsquamous NSCLC
The multicenter phase III CARMEN-LC03 trial did not meet its dual primary endpoints of progression-free and overall survival with the CEACAM5-directed antibody-drug conjugate tusamitamab ravtansine vs standard chemotherapy with docetaxel in previously treated patients with advanced nonsquamous...
New Hope for Patients With HER2-Mutant NSCLC: Durable Responses to Two Novel Targeted Therapies
Two novel oral HER2 tyrosine kinase inhibitors have demonstrated promising efficacy in patients with HER2-mutant non–small cell lung cancer (NSCLC), potentially transforming the treatment landscape for this challenging subset of lung cancer cases. According to data presented at the International...
